Management of neonatal abstinence syndrome in neonates born to opioid maintained women

Drug and Alcohol Dependence

Volumn 87, Issue 2-3, 2007, Pages 131-138

  Ebner, Nina ^a   Rohrmeister, Klaudia ^a   Winklbaur, Bernadette ^a   Baewert, Andjela ^a   Jagsch, Reinhold ^b   Peternell, Alexandra ^a   Thau, Kenneth ^a   Fischer, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Maintenance therapy; Neonatal abstinence syndrome (NAS); Opioid dependence; Pregnancy

Indexed keywords

BUPRENORPHINE; COMPENSAN; METHADONE; MORPHINE; OPIATE; PHENOBARBITAL; UNCLASSIFIED DRUG; VENDAL;

ADULT; APGAR SCORE; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEAD CIRCUMFERENCE; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NEWBORN; OPIATE ADDICTION; PREGNANCY; PRIORITY JOURNAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; APGAR SCORE; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MALE; METHADONE; MORPHINE; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PATIENT SELECTION; PHENOBARBITAL; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 33846804516     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2006.08.024     Document Type: Article

References (65)

1. American Academy of Pediatrics Committee on Drugs. Neonatal drug withdrawal. Pediatrics 101 (1998) 1079-1088
2. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
3. Apgar V. The newborn (Apgar) scoring system: reflections and advice. Pediatr. Clin. North Am. 13 3 (1996) 645-650
4. Auriacombe M., Affelou S., Lavignasse P., Lafitte C., Roux D., Daulouede J.P., and Tignol J. Pregnancy, abortion, and delivery in a cohort of heroin-dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine. Presse Med. 28 (1999) 177
5. Battino D., Estienne M., and Avanzino G. Clinical pharmacokinetics of antiepileptic drugs in pediatric patients. Clin. Pharmacokinet. 29 4 (1995) 257-286
6. Berghella V., Lim P.J., Hill M.K., Cherpes J., Chennat J., and Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am. J. Obstet. Gynecol. 189 2 (2003) 312-317
7. Brown H.L., Britton K.A., Mahaffey D., Brizendine E., Hiett A.K., and Turnquest M.A. Methadone maintenance in pregnancy: a reappraisal. Am. J. Obstet. Gynecol. 179 (1998) 459-463
8. Chiang C.N., and Finnegan L.P. Medications development for the treatment of pregnant addicts and their infants. In: Chiang C.N., and Finnegan L.P. (Eds). NIDA Res. Monogr (1995), US Department of Health and Human Services, Public Health Services, National Institutes of Health, Rockville, MD 149-167
9. Choo R.E., Huestis M.A., Schroeder J.R., Shin A.S., and Jones H.E. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend. 75 (2004) 253-260
10. Coyle M.G., Ferguson A., Lagasse L., Oh W., and Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J. Pediatr. 140 5 (2002) 561-564
11. Dashe J.S., Sheffield J.S., Olscher D.A., Todd S.J., Jackson G.L., and Wendel G.D. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet. Gynecol. 100 (2002) 1244-1249
12. Doberczak T.M., Kandall S.R., and Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet. Gynecol. 81 6 (1993) 936-940
13. European Monitoring Centre for Drugs and Drug Addiction EMCDDA, 1996. Annual Report on the State of the Drugs Problem in the European Union. Lisbon, Portugal: European Comunities.
14. ® Assay Troubleshooting Guide, 1983. Palo Alto CA: Syva Co.
15. FDA/NIDA Guidance. In: State Methadone Maintenance Treatment Guidelines 1992. Center for Substance Abuse Treatment, November. Chaired by Parrino, U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Rockville, MD.
16. Feng T. Substance abuse in pregnancy. Curr. Opin. Obstet. Gynecol. 5 (1993) 16-23
17. Finkelstein, N. and others, 1997. Gender-Specific Substance Abuse Treatment. (National Women's Resource Center for the Prevention and Treatment of Alcohol, Tobacco and Other Drug Abuse and Mental Illness and Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration).
18. Finnegan L.P. Neonatal abstinence. In: Nelson N.M. (Ed). Current Therapy in Neonatal-Perinatal Medicine (1985), Mosby, St. Louis 262
19. Finnegan L.P., and Ehrlich K. Maternal drug use during pregnancy: evaluation and pharmacotherapy for neonatal abstinence. Mod. Methods Pharmacol. Test. Eval. Drugs Abuse 6 (1990) 255-263
20. Finnegan, L.P., Kandall, S.R., 1997. Maternal and neonatal effects of alcohol and drugs, in: Lowinson J.H., Ruiz P., Millman R.B. (Eds.), Langrod J.G. (Assoc.Ed.), Substance Abuse, A Comprehensive Textbook. Baltimore: Williams and Wilkins, second ed., pp. 628-656.
21. Finnegan L.P., and Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman R.A., Friedman S.B., Nelson N., and Seidel H.M. (Eds). Primary Pediatric Care. second ed. (1992), Mosby, St. Louis 1367-1378
22. Finnegan L.P. Addiction and pregnancy: maternal and child issues. In: Tagliamonte A., and Maremani I. (Eds). Drug Related Clinical Problems (1995), Springer, Vienna 137-147
23. Fischer G., Eder H., Jagsch R., Lennkh C., Habeler A., Aschauer H.N., and Kasper S. Maintenance therapy with synthetic opioids within a multidisciplinary program-A stabilizing necessity for pregnant opioid dependent females. Arch. Women Ment. Health 1 (1998) 109-116
24. Fischer G., Jagsch R., Eder H., Gombas W., Etzersdorfer P., Schmidl-Mohl K., Schatten C., Weninger M., and Aschauer H.N. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 94 2 (1999) 231-239
25. Fischer G. Treatment of opioid dependence in pregnant women. Addiction 95 8 (2000) 1141-1144
26. Fischer G., Johnson R.E., Eder H., Jagsch R., Peternell A., Weninger M., Langer M., and Aschauer H.N. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95 2 (2000) 239-244
27. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M., and Aschauer H. Methadone versus buprenorphine in pregnant addicts: A double-blind, double-dummy comparison study. Addiction 101 (2006) 275-281
28. Geistlich S. Course of pregnancy and withdrawal symptoms in newborn infants of female methadone patients and women under morphine substitution treatment. Pregnancy and Drug Misuse (1998), Council of Europe Publishing. 92-871-3784-6 pp. 67-84
29. Glangeaud-Freudenthal N.M.-C., and Barnett B.E.W. Mother-baby inpatient psychiatric care in different countries: data collection and issues-Introduction. Arch. Women Ment. Health 7 (2004) 49-51
30. Gsellhofer B., Küfner H., Vogt M., and Weiler D. European Addiction Index-Manual für Training und Durchführung (1999), Battmannweiler, Schneider
31. Hulse G.K., Milne E., English D.R., and Holman D.J. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 93 7 (1998) 1033-1042
32. Jackson L., Ting A., Mckay S., Galea P., and Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. Arch. Dis. Child Fetal Neonatal Ed. 89 (2004) F300-F304
33. Jarvis M.A.E., and Schnoll S.H. Methadone use during pregnancy. NIDA Res. Monogr. 149 (1995) 58-77
34. Johnson R.E., Jones H.E., and Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 70 (2003) 87-101
35. Johnson K., Gerada C., and Greenough A. Treatment of neonatal abstinence syndrome. Arch. Dis. Child Fetal Neonatal Ed. 88 (2003) F2-F5
36. Jones H.E., Svikis D.S., and Tran G. Patient compliance and maternal/infant outcomes in pregnant drug-using women. Subst. Use Misuse 37 11 (2002) 1411-1422
37. Jones H.E., Johnson R.E., Jasinski D.R., O'Grady K.E., Chisholm C.A., Choo R.E., Crocetti M., Dudas R., Harrow C., Huestis M.A., Jansson L.M., Lantz M., Lester B.M., and Milio L. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: Effects of the neonatal abstinence syndrome. Drug Alcohol Depend. 79 (2005) 1-10
38. Kaltenbach K., and Finnegan L.P. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav. Toxicol. Teratol. 8 (1986) 353-355
39. Kaltenbach K.A. Effects of in-utero opiate exposure: New paradigms for old questions. Drug Alcohol Depend. 36 (1994) 83-87
40. Kaltenbach K., Berghella V., and Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet. Gynecol. Clin. North Am. 25 1 (1998) 139-151
41. Kandall S.R. Treatment Options for Drug-Exposed Infants. NIDA Res. Monogr. 149 (1995) 78-99
42. King J.C. Substance abuse in pregnancy - A bigger problem than you think. Postgrad. Med. 102 3 (1997) 135-150
43. Kron R.F., Litt M., Eng D., Phoenix M.D., and Finnegan L.P. Neonatal narcotic abstinence: Effects of pharmacotherapeutic agents and maternal drug usage on nutritive sucking behavior. J. Pediatr. 88 (1976) 637-641
44. Lacroix I., Berrebi A., Chaumerliac C., Lapeyre-Mestre M., Montastruc J.L., and Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: First result of a prospective study. Addiction 99 (2004) 209-214
45. Langenfeld S., Birkenfeld L., Herkenrath P., Müller C., Hellmich M., and Theison M. Therapy of neonatal abstinence syndrome with tincture of opium or morphine drops. Drug and Alcohol Depend. 77 (2005) 31-36
46. Law K.L., Stroud L.R., LaGasse L.L., Niaura R., Liu J., and Lester B.M. Smoking during pregnancy and newborn neurobehavior. Pediatrics 111 (2003) 1318-1323
47. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S., the Groupe dÉtudes Grossesse et Addictions (GEGA), and 2006. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug and Alcohol Depend. 82 (2006) 250-257
48. Malpas T.J., Darlow B.A., Lennox R., and Horwood L.J. Maternal methadone dosage and neonatal withdrawal. Aust. NZ. J. Obstet. Gynaecol. 35 2 (1995) 175-177
49. Marquet P., Lavignasse P., Gaulier J.M., and Lachátre G. Case study of neonates born to mothers undergoing buprenorphine maintenance treatment. In: Kintz P., and Marquet P. (Eds). Buprenorphine Therapy of Opiate Addiction. (2002), Humana Press, Totowa, New Jersey 125-135
50. McMahon C., Barnett B., Kowalenko N., Tennant C., and Don N. Postnatal depression, anxiety and unsettled infant behaviour. Aust. NZ. J. Psychiatry 35 (2001) 581-588
51. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., and Wisner K.L. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 19 (2005) 2372-2383
52. National Institute on Drug Abuse. National Pregnancy & Health Survey: Drug Use Among Women Delivering Livebirths: 1992. US Department of Health and Human Services (1996), US Government Printing Office, Washington DC
53. Osborn D.A., Cole M.J., and Jeffery H.E. Opiate treatment for opiate withdrawal in newborn infants (Review) (2005) Cochrane Library 2005, Issue 2
54. Osborn D.A., Jeffery H.E., and Cole M.J. Sedatives for opiate withdrawal in newborn infants (Review) (2005) Cochrane Library 2005, Issue 2
55. Pacifico P., Nardelli E., and Panzarotto M.F. Neonatal heroin withdrawal syndrome. Evaluation of different pharmacological treatments. Pharmacol. Res. 21 1 (1989) 63-64
56. Reisinger M. Treatment of four pregnant heroin addicts with buprenorphine. History and outcome. NIDA Res. Monogr. (1995) 261
57. Rohrmeister K., Bernert G., Langer M., Fischer G., Weninger M., and Pollak A. Opiate addiction in gravidity-Consequences for the newborn. Results of an interdisciplinary treatment concept. Z. Gebh. Neonatol. 205 (2001) 224-230
58. Sarenmaa E., Huttunen P., Leppäluoto J., Meretoja O., and Fellman V. Advantages of fentanyl over morphine in analgesia for ventilated newborn infants after birth: a randomised trial. J. Pediatr. 134 2 (1999) 144-150
59. Sarkar S., and Donn S.M. Management of neonatal abstinence syndrome in neonatal intensive care units: A national survey. J. Perinatol. 26 1 (2006) 15-17
60. Substance Abuse and Mental Health Services Administration (SAMHSA), 2001. Summary of Findings from the 2000 National Household Survey on Drug Abuse. Rockville (MD), Department of Health and Human Services. DHHS Publication no. SMA 01-3549, NHS DA Series 11-2.
61. Substance Abuse and Mental Health Services Administration (SAMHSA), 2004a. DASIS Report, Heroin-changes in how it is used: 1992-2002. Office of Applied Studies.
62. Substance Abuse and Mental Health Services Administration (SAMHSA). 2004b. DASIS Report, Nonmedical Use of Prescription Pain Relievers: 1992-2002. Office of Applied Studies.
63. Shaw N.J., and McIvor L. Neonatal abstinence syndrome after maternal treatment. Arch. Dis. Child 71 (1994) F203-F205
64. Theis J.G.W., Elby P., Ikizler Y., and Koren G. Current management of the neonatal abstinence syndrome: A critical analysis of the evidence. Biol. Neonate 71 (1997) 345-356
65. Westat Inc. Drug Use among Women Delivering Livebirths. National Pregnancy and Health Survey: 1992 (1996), National Institute of Drug Abuse, Rockville, MD